Vaccination with recombinant paramyosin in Montanide ISA206 protects against Schistosoma japonicum infection in water buffalo

Schistosome Vaccines for Domestic Animals

“…The same team showed that the rSj-97 vaccine, adjuvanted with Montanide ISA 206, was safe, well tolerated and robustly immunogenic among water buffaloes resident in four villages in Leyte, the Philippines, an area highly endemic for schistosomiasis japonica [ 64 ]. They conducted three vaccine trials (in 2008, in 2013 and in 2016) to assess the level of protection generated in water buffaloes with the rSj-97 vaccine; animals received and tolerated well three doses (250 μg/dose or 500 μg/dose) of rSj97 plus Montanide ISA 206 at 4 weekly intervals before a challenge infection with 1000 S. japonicum cercariae [ 58 ]. The 3 × 250 μg/dose of rSj97 (2008 and 2013 trials) did not result in a significant reduction in worm burden in vaccinated animals compared with controls injected with ISA 206 emulsified with lyophilisation buffer, but the increased dosage (3 × 500 μg/dose of rSj97) in the 2013 and 2016 trials resulted in a significantly lower worm burden (by 57.8% in both trials) in vaccinated water buffaloes compared with controls [ 58 ].…”

“…They conducted three vaccine trials (in 2008, in 2013 and in 2016) to assess the level of protection generated in water buffaloes with the rSj-97 vaccine; animals received and tolerated well three doses (250 μg/dose or 500 μg/dose) of rSj97 plus Montanide ISA 206 at 4 weekly intervals before a challenge infection with 1000 S. japonicum cercariae [ 58 ]. The 3 × 250 μg/dose of rSj97 (2008 and 2013 trials) did not result in a significant reduction in worm burden in vaccinated animals compared with controls injected with ISA 206 emulsified with lyophilisation buffer, but the increased dosage (3 × 500 μg/dose of rSj97) in the 2013 and 2016 trials resulted in a significantly lower worm burden (by 57.8% in both trials) in vaccinated water buffaloes compared with controls [ 58 ]. The trialled rSj97/ISA206 vaccine resulted in a mixed immune response with induction of both IgG1 and IgG2 anti-paramyosin antibodies, but no conclusive correlation was found between isotype distribution and protection [ 58 ].…”

“…The 3 × 250 μg/dose of rSj97 (2008 and 2013 trials) did not result in a significant reduction in worm burden in vaccinated animals compared with controls injected with ISA 206 emulsified with lyophilisation buffer, but the increased dosage (3 × 500 μg/dose of rSj97) in the 2013 and 2016 trials resulted in a significantly lower worm burden (by 57.8% in both trials) in vaccinated water buffaloes compared with controls [ 58 ]. The trialled rSj97/ISA206 vaccine resulted in a mixed immune response with induction of both IgG1 and IgG2 anti-paramyosin antibodies, but no conclusive correlation was found between isotype distribution and protection [ 58 ]. The group also reported undertaking a trial in buffaloes with the rSj97-ISA206 vaccine followed by six months of community-based field exposure after vaccination [ 58 ], but the results have not yet been released.…”

“…The trialled rSj97/ISA206 vaccine resulted in a mixed immune response with induction of both IgG1 and IgG2 anti-paramyosin antibodies, but no conclusive correlation was found between isotype distribution and protection [ 58 ]. The group also reported undertaking a trial in buffaloes with the rSj97-ISA206 vaccine followed by six months of community-based field exposure after vaccination [ 58 ], but the results have not yet been released.…”

T cell mediated immunity to Schistosoma japonicum infection and vaccination

“…Sj97 is now in early preclinical testing with process development and further proof of concept studies taking place in mice and water buffalo [135,174,176].…”